Read this company snapshot
Daily valuation snapshot
Sonoma Pharmaceuticals, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.23
- Market capitalization (USD)
- $5,889,762.75
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.89
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SNOA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SNOA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing SNOA with another company.
| Daily close (USD) | $1.23 |
| Market capitalization (USD) | $5,889,762.75 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.89 |
No matching rows. Clear the filter to see all records.
Read SNOA's valuation metrics
Company size
Sonoma Pharmaceuticals, Inc. Common Stock's recorded market capitalization is $5,889,762.75. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
SNOA's recorded price-to-book ratio is 0.89. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Sonoma Pharmaceuticals, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about SNOA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow SNOA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.